The genomic complexity of primary human prostate cancer

Michael F. Berger, Michael S. Lawrence, Francesca Demichelis, Yotam Drier, Kristian Cibulskis, Andrey Sivachenko, Andrea Sboner, Raquel Esgueva, Dorothee Pflueger, Carrie Sougnez, Robert C. Onofrio, Scott L. Carter, Kyung Park, Lukas Habegger, Lauren Ambrogio, Timothy R. Fennell, Melissa Parkin, Gordon Saksena, Douglas Voet, Alex H. Ramos, Trevor J. Pugh, Jane Wilkinson, Sheila Fisher, Wendy Winckler, Scott Mahan, Kristin Ardlie, Jennifer Baldwin, Jonathan W. Simons, Naoki Kitabayashi, Theresa Y. MacDonald, Philip W. Kantoff, Lynda Chin, Stacey Gabriel, Mark Gerstein, Todd R. Golub, Matthew Meyerson, Ashutosh Tewari, Eric S. Lander, Gad Getz, Mark A. Rubin, Levi A. GarrawayNature 2011 · DOI

Abstract

Prostate cancer is the second most common cause of male cancer deaths in the United States. However, the full range of prostate cancer genomic alterations is incompletely characterized. Here we present the complete sequence of seven primary human prostate cancers and their paired normal counterparts. Several tumours contained complex chains of balanced (that is, 'copy-neutral') rearrangements that occurred within or adjacent to known cancer genes. Rearrangement breakpoints were enriched near open chromatin, androgen receptor and ERG DNA binding sites in the setting of the ETS gene fusion TMPRSS2-ERG, but inversely correlated with these regions in tumours lacking ETS fusions. This observation suggests a link between chromatin or transcriptional regulation and the genesis of genomic aberrations. Three tumours contained rearrangements that disrupted CADM2, and four harboured events disrupting either PTEN (unbalanced events), a prostate tumour suppressor, or MAGI2 (balanced events), a PTEN interacting protein not previously implicated in prostate tumorigenesis. Thus, genomic rearrangements may arise from transcriptional or chromatin aberrancies and engage prostate tumorigenic mechanisms.

Introduction: Beyond the Exome

Prostate cancer remains a significant clinical challenge and a leading cause of cancer-related mortality in men. While specific drivers like the TMPRSS2–ERG fusion and PTEN deletions have been identified, the broader genomic landscape—particularly the non-coding "dark matter"—has remained largely unexplored. Previous genomic studies focused heavily on the exome, which represents only about 1% of the total DNA. This landmark study utilizes whole-genome sequencing (WGS) to provide a high-resolution map of primary human prostate cancer, uncovering a complex architecture of structural rearrangements that drive the disease.

Methods: A High-Resolution Genomic Map

To characterize the full spectrum of genomic alterations, the researchers performed paired-end, massively parallel sequencing on seven primary human prostate tumors and their matched normal counterparts. Achieving a mean sequence coverage of approximately 30-fold, the study identified a median of 90 rearrangements per genome, ranging from 43 to 213. These structural variations were visualized using Circos plots, which reveal the intricate web of inter- and intra-chromosomal translocations characteristic of these tumors. Candidate rearrangements were further validated using multiplexed PCR and Fluorescence In Situ Hybridization (FISH) on an independent cohort of over 90 tumors.

Circos plots illustrating the complex landscape of genomic rearrangements across seven primary prostate cancer genomes. Each line represents a translocation event, highlighting the structural instability of the disease.

The "Closed Chain" Phenomenon

A striking discovery of this research is the presence of "balanced" or "copy-neutral" rearrangements. Unlike random genomic breaks that lead to large-scale deletions or duplications, these events involve coordinated swaps of DNA segments between chromosomes without a net loss of genetic material. These "closed chains" often occur within or adjacent to critical cancer genes, suggesting a highly coordinated, albeit catastrophic, mechanism of genomic instability.

Comprehensive analysis of genomic rearrangements. (a) Schematic of balanced "closed chain" rearrangements. (b, c) Detailed mapping of rearrangements in specific tumors, showing how these events disrupt key genes like ERG, TMPRSS2, and PTEN-interacting proteins.

Chromatin State and Genomic Damage

The study integrated genomic breakpoint data with epigenetic markers using ChIP-seq data. The results showed that the location of genomic breaks is highly non-random and dictated by the cell's epigenetic state. In tumors harboring the TMPRSS2–ERG fusion, breakpoints were significantly enriched in regions of open, active chromatin and near Androgen Receptor (AR) binding sites. In contrast, tumors lacking the fusion showed enrichment of breaks in closed, repressed chromatin regions (marked by H3K27me3). This suggests that the cell's transcriptional machinery and chromatin landscape directly influence the genesis of genomic aberrations.

Key Results and Novel Tumor Suppressors

Beyond confirming known drivers, the study identified recurrent disruptions in MAGI2 and CADM2. MAGI2 is of particular interest as it interacts with the well-known tumor suppressor PTEN; its disruption provides a novel alternative pathway to activate pro-growth PI3K signaling. The study also identified SPOP and SPTA1 as recurrently mutated genes. Notably, primary prostate cancer exhibited a relatively low burden of point mutations (median of 3,866 somatic base mutations per tumor) compared to cancers like melanoma, highlighting that structural rearrangements are the primary drivers in this malignancy.

Conclusion and Future Directions

This whole-genome perspective reveals that prostate cancer is defined by complex, transcriptionally-linked genomic rearrangements. The discovery of "closed chains" and the involvement of novel genes like MAGI2 expand our understanding of prostate tumorigenesis. While the discovery cohort was small, the validation in larger cohorts confirms the importance of these findings. Future work will focus on whether these complex rearrangements can serve as biomarkers for high-risk patients and if targeting the identified pathways could lead to new therapeutic options.

Summary updated

Abstract

Prostate cancer is the second most common cause of male cancer deaths in the United States. However, the full range of prostate cancer genomic alterations is incompletely characterized. Here we present the complete sequence of seven primary human prostate cancers and their paired normal counterparts. Several tumours contained complex chains of balanced (that is, 'copy-neutral') rearrangements that occurred within or adjacent to known cancer genes. Rearrangement breakpoints were enriched near open chromatin, androgen receptor and ERG DNA binding sites in the setting of the ETS gene fusion TMPRSS2-ERG, but inversely correlated with these regions in tumours lacking ETS fusions. This observation suggests a link between chromatin or transcriptional regulation and the genesis of genomic aberrations. Three tumours contained rearrangements that disrupted CADM2, and four harboured events disrupting either PTEN (unbalanced events), a prostate tumour suppressor, or MAGI2 (balanced events), a PTEN interacting protein not previously implicated in prostate tumorigenesis. Thus, genomic rearrangements may arise from transcriptional or chromatin aberrancies and engage prostate tumorigenic mechanisms.
BibTeX
@inproceedings{berger2011genomic,
  author = {Michael F. Berger and Michael S. Lawrence and Francesca Demichelis and Yotam Drier and Kristian Cibulskis and Andrey Sivachenko and Andrea Sboner and Raquel Esgueva and Dorothee Pflueger and Carrie Sougnez and Robert C. Onofrio and Scott L. Carter and Kyung Park and Lukas Habegger and Lauren Ambrogio and Timothy R. Fennell and Melissa Parkin and Gordon Saksena and Douglas Voet and Alex H. Ramos and Trevor J. Pugh and Jane Wilkinson and Sheila Fisher and Wendy Winckler and Scott Mahan and Kristin Ardlie and Jennifer Baldwin and Jonathan W. Simons and Naoki Kitabayashi and Theresa Y. MacDonald and Philip W. Kantoff and Lynda Chin and Stacey Gabriel and Mark Gerstein and Todd R. Golub and Matthew Meyerson and Ashutosh Tewari and Eric S. Lander and Gad Getz and Mark A. Rubin and Levi A. Garraway},
  title = {{The genomic complexity of primary human prostate cancer}},
  booktitle = {Nature},
  year = {2011},
  doi = {10.1038/nature09744},
}
Figure